Clinical development of human vaccine candidates against Shigella flexneri: a systematic review of clinical trials.
Shigella flexneri remains a leading cause of shigellosis, particularly in low- and middle-income countries, where it contributes substantially to childhood morbidity, mortality, and the growing burden of antimicrobial re Large multicenter efficacy trials, standardized immunological outcome measures, and multivalent vaccine strategies will be essential to accelerate the development of an effective S. Full text review required for further details.
Shigella flexneri remains a leading cause of shigellosis, particularly in low- and middle-income countries, where it contributes substantially to childhood morbidity, mortality, and the growing burden of antimicrobial re Large multicenter efficacy trials, standardized immunological outcome measures, and multivalent vaccine strategies will be essential to accelerate the development of an effective S. Full text review required for further details.
What the study was
- Study design
- Systematic Review
- Category
- Other
- Maturity
- Potentially Practice-Changing
- Journal
- Vaccine
Why it surfaced
Scored 8/10 (Systematic Review; novelty=2, relevance=2, design_quality=2, population_or_unmet_need=2). HIGH priority.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.